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Regulation of caspase-3 processing by cIAP2 controls
the switch between pro-inflammatory activation and
cell death in microglia
E Kavanagh1,3, J Rodhe1,3, MA Burguillos1, JL Venero2 and B Joseph*,1
The activation of microglia, resident immune cells of the central nervous system, and inflammation-mediated neurotoxicity are
typical features of neurodegenerative diseases, for example, Alzheimer's and Parkinson's diseases. An unexpected role of
caspase-3, commonly known to have executioner role for apoptosis, was uncovered in the microglia activation process. A central
question emerging from this finding is what prevents caspase-3 during the microglia activation from killing those cells? Caspase-3
activation occurs as a two-step process, where the zymogen is first cleaved by upstream caspases, such as caspase-8, to form
intermediate, yet still active, p19/p12 complex; thereafter, autocatalytic processing generates the fully mature p17/p12 form of the
enzyme. Here, we show that the induction of cellular inhibitor of apoptosis protein 2 (cIAP2) expression upon microglia activation
prevents the conversion of caspase-3 p19 subunit to p17 subunit and is responsible for restraining caspase-3 in terms of activity
and subcellular localization. We demonstrate that counteracting the repressive effect of cIAP2 on caspase-3 activation, using small
interfering RNA targeting cIAP2 or a SMAC mimetic such as the BV6 compound, reduced the pro-inflammatory activation of
microglia cells and promoted their death. We propose that the different caspase-3 functions in microglia, and potentially other cell
types, reside in the active caspase-3 complexes formed. These results also could indicate cIAP2 as a possible therapeutic target to
modulate microglia pro-inflammatory activation and associated neurotoxicity observed in neurodegenerative disorders.
Cell Death and Disease (2014) 5, e1565; doi:10.1038/cddis.2014.514; published online 11 December 2014
Introduction
Microglia cells are the resident immune cells of the central
nervous system, constantly screening the brain environment.
They express surface receptors to detect changes in their
environment due to brain damage or infections. An important
family of these sensors is the toll-like receptor (TLR) family.1
Although microglia are necessary for normal function,
uncontrolled and over-activated microglia can result in
disastrous neurotoxic consequences. Indeed, microglia are a
predominant source of pro-inflammatory mediators including
cytokines, complement factors, free radicals, nitric oxide (NO),
chemokines and prostanglandins, all of which potentially
contribute to further neuronal dysfunction and death.1–3
Activation of microglia towards a pro-inflammatory phenotype
and the resulting inflammatory response are typical features of
neurodegenerative and neuroinflammatory disorders and
have an important role in the demise of different neuronal
populations. In fact, evidence from numerous clinical neuro-
pathological observations and in vivo studies suggest a
prominent role of activated microglia in the initiation and/or
aggravation of neurodegenerative disorders, including Alzhei-
mer's disease (AD) and Parkinson's disease (PD).1,3–5
Caspases, a family of cysteinyl aspartate-specific pro-
teases, are best known as executioners of apoptotic cell
death and their activation are considered to be a commitment
to cell death.6 However, certain caspases also function as
regulatory molecules for immunity, cell differentiation and cell
fate determination. We have characterized a novel and
unexpected mechanism involved in the activation of microglia
in response to different TLR4 ligands. This mechanism
involves a caspase-dependent signaling governing microglia
activation. We showed that the orderly activation of caspase-8
and caspase-3 (so-called apoptotic caspases) regulate
microglia activation via a protein kinase C (PKCδ)-dependent
pathway. We found that the stimulation of microglia with
various TLR ligands activates caspase-8 and caspase-3 in
microglia without triggering cell death in vitro and in vivo.
Knockdown or chemical inhibition of each of these caspases
hindered microglia activation. Moreover, we provided compel-
ling evidence that these caspases are activated in microglia in
the ventral mesencephalon of PD and the frontal cortex of AD
subjects.5
One central question emerging from the discovery that the
apoptotic caspases regulate microglia activation is, which
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mechanism prevents them from killing the microglia cells? In
this study, we show that the control of caspase-3 cleavage by
cellular inhibitor of apoptosis protein 2 (cIAP2) dictates
whether microglia will undergo pro-inflammatory activation or
apoptosis.
Results
Distinctive caspase-3 processing profile in microglia
cells after pro-inflammatory stimulus. In an attempt to
characterize the molecular events that hinder active caspase-3
from killing microglia, a biochemical analysis of caspase-3
processing was performed in activated microglia cells versus
dying microglia cells. Caspase-3 is synthesized as a single-
chain inactive zymogen, containing a prodomain, as well as
large and small subunits that include the residues required for
substrate recognition and cleavage. Caspase-3 activation
occurs in two stages.7 First, caspase-3 proforms are cleaved
by upstream caspases, such as active caspase-8, at Asp175
to generate intermediate, yet still active, heterotetramer
complexes consisting of two p19 and two p12 peptides
(p19/p12 complexes). The second stage involves removal of
the short prodomain from the p19 peptides by autocatalytic
processing, and cleavage at residue Asp28, to generate the
fully mature p17/p12 form of the enzyme (see scheme in
Figure 6). BV2 microglia cells were stimulated with lipopoly-
saccharide (LPS), the major component of Gram-negative
bacterial walls and a ligand for TLR4, to investigate the
processing of caspase-3 in activated microglia. Of note,
intracerebral delivery of LPS, which leads in vivo to microglia
activation and neuronal injury, is used as model for brain
inflammation.8,9 Immunoprecipitation using a polyclonal anti-
body raised against cleaved caspase-3 Asp175, which
recognized both p17 and p19 subunit, was used to isolate
and concentrate caspase-3 subunits. Subsequent immuno-
blot analysis using the same antibody revealed that upon
LPS-induced microglia activation, the processing of the p19
N-terminal caspase-3 fragment containing the prodomain to
the active p17 fragment is prevented (Figure 1a). In contrast
to LPS treatment, exposure of BV2 microglia cells to a death
stimulus such as staurosporine (STS) led to a significantly
greater caspase-3 processing and appearance of the active
p17 fragment (Figure 1a). This results are in agreement with
the reported moderate D(OMe)E(OMe)VD(OMe)-ase (DEVD-
ase) activity, which reflects caspase-3 function as protease,
observed upon treatment of BV2 microglia cells with various
pro-inflammogens, including LPS5 (Figure 3f).
Cytoplasmic retention of active caspase-3 in pro-
inflammatory stimulated microglia cells. We hypothe-
sized that during microglia activation, the avoidance of p19
to p17 caspase-3 conversion controls both the strength of
activity and the localization of caspase-3. It is worth noting
that nuclear localization of active caspase-3 appears to be
regulated by an active transport system.10,11 In addition,
removal of the short prodomain from caspase-3 fragments
(i.e., conversion of p19 to p17) contributes to its nuclear
relocalization.12 We previously reported using confocal cell
imaging that following LPS treatment of microglia BV2 cells,
cleaved caspase-3 Asp175 is found to be located outside the
nuclear compartment.5 However, this experimental setup
does not allow for the discrimination between the possible
p17 and p19 caspase-3 subunits. To further characterize and
reveal the subcellular localization of those caspase-3 sub-
units in activated microglia, immunoblot analysis for cleaved
caspase-3 was performed on both nuclear and cytoplasmic
subcellular fractions. The p19 subunit was predominantly
found to be localized in the cytosol in both the activated and
dying microglia. In contrast, the p17 subunit, which was
detected in the dying STS-treated microglia, was detected in
both the cytoplasmic and nuclear compartments (Figure 1b).
Collectively, these data indicate the presence of cytoplasmic
active caspase-3 in pro-inflammatory-activated microglia, in
contrast to whole-cell (cytoplasm/nucleus) caspase-3 activa-
tion in the dying cells. These conclusions are further
supported by our previous finding that PKCδ, a cytoplasmic
caspase-3 substrate, but not poly(ADP-ribose) polymerase
(PARP-1) a nuclear caspase-3 nuclear substrate, is found to
be cleaved in microglia cells in response to LPS treatment.5
Pro-inflammatory activation of microglia is associated
with induction of caspase-3-interacting protein cIAP2.
Thereafter, we aimed at elucidating the molecular mechan-
ism that controls the restricted caspase-3 processing in
microglia cells and thereby prevents their death and
contributes to their activation towards a pro-inflammatory
phenotype. Given the devastating consequences of caspase
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Figure 1 Distinctive caspase-3 processing profile in pro-inflammatory activated
versus dying microglia. BV2 microglia cells were treated with 1 μg/ml LPS for 24 h or
0.1 μM STS for 3 h to promote pro-inflammatory activation or cell death, respectively.
(a) Immunoblot analysis demonstrates presence of the p19 caspase-3 subunit in the
immune complexes formed after pull down with cleaved caspase-3 Asp175 antibody,
which recognizes both p17 and p19 subunits, in LPS-treated microglia. Immune
complexes from STS-treated microglia contained both p17 and p19 caspase-3
subunits. (b) Subcellular fractionation illustrates the restricted cytoplasmic localization
of p19 subunit, in contrast to the p17 subunit that was found to localize in both the
cytoplasmic and the nuclear fractions
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activation, cells have evolved mechanisms to regulate
caspase activity. Inhibitors of apoptosis protein (IAPs)
constitute an important class of apoptosis regulators func-
tioning at the level of caspase activity.13,14 They recognize,
through baculovirus IAP repeat (BIR) domains, a specific
sequence found on caspases called the IAP-binding motif
(IBM). The IBM is found on the N-terminal of the p19 peptide
but is absent (through autocatalytic cleavage) from the p17
peptide. X-linked IAP (XIAP), the prototypical IAP in
mammals, inhibits apoptosis largely through direct inhibition
of the initiator caspase-9 and the effector caspase-3 and
caspase-7. Two additional IAP family members, cIAP1 and
cIAP2, were once thought to also inhibit caspases, but more
recent studies suggest that these IAPs bind to effector
caspases but do not inhibit their proteolytic activities.15–17 It is
very attractive to envisage that upregulation of IAPs during
the caspase-mediated microglia activation is responsible for
holding back caspase-3 in terms of activity and subcellular
localization and therefore would be a key molecular event in
preventing the cell death. Therefore, the mRNA expression
levels of XIAP, cIAP1 and cIAP2 in microglia cells after LPS
treatment was analyzed. Remarkably, only cIAP2 mRNA
expression levels were found to be increased in microglia up
to 6 h post LPS treatment (Figure 2a). Interestingly, cIAP1
mRNA expression levels were found to be reduced in LPS-
treated microglia cells. Immunoblot analysis confirmed the
increase in cIAP2 expression at protein levels in a time-
dependent manner upon microglia activation in response to
LPS treatment (Figures 2b and c). Worth a notice, LPS
treatment has been reported to induce cIAP2 expression in
macrophages.18 In addition, cIAP2-deficient mice exhibit
profound resistance to LPS-induced sepsis.19 Caspase-3–
cIAP2 interaction has previously been reported in various
cellular model systems.16,20,21 Further, protein–protein inter-
action between caspase-3 and cIAP2 was confirmed in
microglia using an in situ proximity ligation assay (PLA)
(Figures 3a and b). The predominant cytoplasmic localization
of cIAP2 was confirmed by immunoblot analysis performed
on both the nuclear and cytoplasmic subcellular fractions
(Figure 3c).
cIAP2 controls the conversion of p19 into p17 caspase-3
subunit in microglia. As previously mentioned, the IBM is
found in the short prodomain of caspase-3 and is present in
the p19 peptide but is absent from the p17 peptide.
Interestingly, the processing of the caspase-3 p19 fragment
to the p17 fragment has been suggested to be controlled by
cIAP2.22 To investigate the functional role of the caspase-3–
cIAP2 association, we next determined the effect of cIAP2
silencing using small interfering RNA (siRNA) (Figures 3d
and e) on the processing of caspase-3 upon LPS-induced
BV2 microglia activation. Immunoprecipitation using the
cleaved caspase-3 Asp175 antibody, which recognized p17
and p19 subunit, was used to isolate and concentrate
caspase-3 subunits. Subsequent immunoblot analysis using
the same antibody revealed that overall cleaved caspase-3
levels were increased and the generation of the caspase-3
p17 fragment in LPS-treated microglia was increased by 1.5-
fold in cells transfected with a cIAP2 siRNA as compared with
control siRNA (Figures 3d and e). DEVD-ase activity assay
also revealed that cIAP2 siRNA positively affected caspase-
3-like activity in LPS-treated microglia cells (Figure 3f).
cIAP2 silencing promotes cell death and hinders micro-
glia activation upon pro-inflammatory stimulus. The
levels of cIAP2 can help to determine the threshold of
caspase-3 activity that a cell can withstand before succumb-
ing to the irreversible caspase cascade leading to apoptosis.
Moreover, the control of caspase-3 p19 to p17 subunit
conversion by cIAP2 can regulate the subcellular localization
of active caspase-3, that is, p19/p12 complexes being
cytoplasmic and p17/p12 complexes exhibiting the ability to
relocate into the nucleus. The selective localization of active
caspase-3 complexes can in turn regulate their ability to
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Figure 2 Levels of cIAP2 increase in BV2 microglia cells after LPS treatment. (a) mRNA levels of cIAP1, cIAP2 and XIAP were assessed by qPCR in untreated and 6 h LPS-
treated BV2 microglia cells. (b) LPS-induced cIAP2 protein expression was analyzed by immunobloting for the indicated time points. iNOS expression was used as a marker for
microglial pro-inflammatory activation and β-actin used as standard for equal loading of protein. (c) Quantification of cIAP2 protein expression is depicted for LPS-treated BV2
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process cytoplasmic substrates (e.g., PKCδ) or nuclear
substrates (e.g., PARP) and thereby affect different biological
processes such as microglia pro-inflammatory activation or
apoptotic cell death, respectively5 (see scheme in Figure 6).
In agreement, increased PARP cleavage was observed in
LPS-treated BV2 cells, where cIAP2 expression was targeted
using an siRNA strategy (Figure 3g). As a result, increased
cell death, as monitored by the appearance of fragmented,
damaged or condensed nuclei and apoptotic phosphatidyl-
serine (PS) exposure, was observed upon cIAP2 silencing in
LPS-activated microglia (Figure 3h and supplementary
Figure S1a). Following LPS treatment, BV2 microglia cells
did show features of activated microglia, such as inducible
NO synthase (iNOS) expression and production of cytokine
interleukin-1β (IL-1β) (Figures 4a and e). Remarkably, when
we transfected BV2 microglia cells with siRNA targeting
cIAP2 (Figures 4a and b), LPS treatment failed to induce
iNOS mRNA and protein expression (Figures 4a, c and d)
and production of IL-1β cytokine (Figure 4e) as effectively.
Collectively, these data indicated that cIAP2 silencing affects
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both the microglial cell death and activation under a pro-
inflammatory stimulus like LPS. Thus, disruption of the cIAP2
control of microglial caspase-3 activation appears to exhibit
pleotropic effects, possibly as a result of the promotion of p19
to p17 caspase-3 conversion, that should result in an
increase of the p17/p12 complexes at the expense of the
p19/p12 complexes, which regulate cell death and activation,
respectively.
SMAC mimetic BV6 enhances caspase-3 activation and
promotes cell death of LPS-activated microglia. Mamma-
lian cells possess natural antagonists of IAP-mediated
caspase inhibition such as SMAC (second mitochondria-
derived activator of caspases) also known as DIABLO (direct
inhibitor of apoptosis-binding protein with low isoelectric
point).23,24 SMAC facilitates activation of apoptotic caspases
by releasing these proteases from the inhibitory interaction
with IAPs. In the case of XIAP, SMAC binding results in its
dissociation from the bound caspases. In contrast, in the
case of cIAP1/2, SMAC binding triggers autoubiquitination
and proteasomal degradation of these molecules. Com-
pounds mimicking the inhibitory effect of SMAC on IAPs,
referred as SMAC mimetics, have been developed with the
aim to achieve sensitization of cells to apoptotic cell death.
BV6, a SMAC mimetic, has been shown to induce rapid
proteasomal degradation of cIAPs, and thereby abrogate
cIAPs-mediated inhibition of caspases, and induce cell
death.25,26 In view of the importance of cIAP2 in the
regulation of caspase-3 processing upon pro-inflammatory
activation of microglia, we decided to analyze the effects of
the SMAC mimetic BV6 on BV2 microglia cells. We first
selected a concentration of the BV6 compound (i.e., 1 μM),
which only induces moderate cell death in microglia, but
reduces efficiently cIAP2 protein expression levels in those
cells as investigated by fluorescence-activated cell sorting
(FACS) analysis (Figure 5a). Furthermore, BV6 treatment
was also efficient at counteracting LPS-induced cIAP2
expression in microglia. These results are in agreement with
previous studies that demonstrated the proteolytic degrada-
tion of cIAP1/2 protein upon BV6 treatment in various cell
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Figure 4 cIAP2 silencing hinders microglia pro-inflammatory activation upon LPS treatment. Knockdown of cIAP2 expression using siRNA prevents LPS-induced expression
of iNOS in BV2 microglia cells. (a) Representative immunoblot using anti-iNOS, anti-cIAP2 and anti-actin antibodies. Quantification of (b) cIAP2 and (c) iNOS protein expression.
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types including myeloid cells.27 Noteworthy, the appearance
of cleaved caspase-3 Asp175 and associated DEVD-ase
activity were found increased in BV6-treated microglia cells.
Moreover, BV6 treatment significantly enhanced these two
parameters in LPS-treated microglia cells (Figures 5b and c).
In contrast, decreased LPS-induced IL-1β expression was
observed upon exposure to the BV6 compound (Figure 5d).
Finally, in agreement with the above described negative
impact of cIAP2 on caspase-3 processing towards the
death-effective p17/p12 complexes, the SMAC mimetic BV6
promoted cell death of LPS-treated microglia (Figure 5e and
supplementary Figure S1b and supplementary Figure S2).
Altogether, these results demonstrated that the SMAC
mimetic BV6 is indeed able to suppress the inhibitory effect
of cIAP2 on full maturation of caspase-3 complexes and
thereby promote microglial cell death (Figure 6).
Discussion
There is compelling evidence that within the caspase family of
cysteinyl aspartate-specific proteases, caspase-3 can per-
form as a key executor of the apoptotic cell death program.28
Activated caspase-3 leads, for example, to the processing of
PARP, a caspase-3 nuclear substrate, and thereby contributes
to demise of the cell. Nevertheless, increasing number of
studies likewise call attention to the non-apoptotic functions for
this so-called apoptotic caspase, including in the neuronal cell
population. For instance, regulation of synaptic plasticity and
function has been shown to be associated with caspase-3
activation.29 The non-apoptotic functions of caspase-3 in the
brain are not limited to the neuronal population. Indeed, we
recently uncovered an unexpected role for caspase-3 in the
process of microglia pro-inflammatory activation.5 Activation
of microglia and inflammation-mediated neurotoxicity are
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believed to have important roles in the pathogenesis of several
neurodegenerative disorders. We showed that orderly activa-
tion of caspase-8 and caspase-3 regulates microglia activa-
tion through a PKCδ-dependent pathway. Thus, caspase-3
activation and subsequent proteolytic activation or inactivation
of cytoplasmic (e.g., PKCδ) or nuclear (e.g., PARP) caspase-3
downstream targets can lead to rather contrasting effects,
microglia pro-inflammatory activation or apoptotic cell death.
What restricts caspase-3 activation in terms of subcellular
localization and intensity might provide an answer to the
conflicting functions of caspase-3 in microglia cells. We
uncovered that different profiles of caspase-3 processing
can be observed in activated versus dying microglia cells, that
is, the p19 caspase-3 subunit seems to occur predominately in
activatedmicroglia, whereas the p17 caspase-3 subunit arises
mostly during the apoptosis. Interestingly, the processing of
the cytosolic caspase-3 p19 fragment to the p17 fragment,
which has the ability to relocate into the nuclear compartment,
has been suggested to be controlled by cIAP2.22 We and
others report that cIAP2 protein expression is upregulated in
microglia and macrophages upon treatment with a proinflam-
mogen such as LPS.19 In addition, cIAP2-deficient mice have
been reported to exhibit profound resistance to LPS-induced
sepsis, specifically because of an attenuated inflammatory
response.19 We demonstrate that counteracting the repres-
sive effect of cIAP2 on caspase-3 activation, using siRNA
targeting cIAP2 itself or a SMAC mimetic such as the BV6
compound, reduced the pro-inflammatory activation of micro-
glia cells and promoted their death. On the basis of our
findings, we propose that the different caspase-3 functions in
microglia, and potentially other cell types, resides in the active
caspase-3 complexes formed (Figure 6). Cytoplasmic
caspase-3 p19/p12 complexes would be responsible for the
pro-inflammatory activation of microglia, whereas the nuclear
caspase-3 p17/p12 complexes would promote apoptosis in
microglia. Collectively, our data reveal that cIAP2 may work as
a molecular switch for the decision between pro-inflammatory
activation and apoptosis in microglia. These results also could
indicate cIAP2 as a possible therapeutic target to modulate
microglia pro-inflammatory activation and associated neuro-
toxicity observed, for example, in neurodegenerative disor-
ders. SMAC mimetics, which oppose the effect of cIAP2,
would also be seen as potential candidate drugs. In fact,
SMAC mimetics, alone or in association, are already
considered as a new class of targeted drugs for the treatment
of solid tumors and hematologic cancers with ongoing clinical
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Figure 6 Scheme illustrating the effect of cIAP2 on the caspase-3 activation steps and consequently biological functions. Pro-caspase-3 is cleaved by upstream caspases,
such as active caspases-8, at Asp175 to generate intermediate, yet still active, p19/p12 complexes. Thereafter, autocatalytic processing at residue Asp28 and removal of the short
prodomain from the p19 peptides, generate p17/p12 complexes that form the fully mature form of the enzyme and translocate to the nucleus. In turn, p19/p12 and p17/p12
complexes can cleave substrates in the cytoplasmic or cytoplasmic/nuclear cell compartment, respectively, and thereby regulate pro-inflammatory activation or apoptotic cell
death of the microglia cells. Upon pro-inflammatory stimulation, upregulated cIAP2 binds to caspase-3 prodomain and prevents the p19 to p17 caspase-3 subunit conversion
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trials (www.clinicaltrials.gov).30 Our results further illustrate
the potential impact of SMAC mimetics on microglia-
associated brain diseases, comporting a neuroinflammatory
component, such as neurodegenerative disorders, brain
trauma or even stroke. However, the benefit of killing microglia
cells, instead of suffering their pro-inflammatory activation
remains to be proven and would require further investigations.
In summary, we show that the cIAP2 is involved in regulating
caspase-3 activation and thereby functions in microglia. We
conclude that regulation of the conversion of caspase-3 p19
subunit to p17 subunit in those cells can also be used to
modulate microglial biological functions.
Materials and Methods
Cell culture, transfection and treatments. Murine microglial BV2 cell
line was cultured as described.31 Cells were maintained in DMEM medium (Gibco
BRL, Carlsbad, CA, USA) supplemented with penicillin (100 μg/ml), streptomycin
(100 μg/ml) and 10% fetal calf serum (FCS), reduced to 5% FCS while performing
the experiments. Transfection of BV2 cells was carried out using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s recommendation.
Predesigned and tested ON-TARGETplus SMARTpool siRNA against mouse
BIRC3 (NM-007464; #L-062425-00-0005) and non-targeted sequence (#D-001810-
01-05) were purchased from Thermo Scientific (Walthman, MA, USA). Cells were
treated with 1 μg/ml LPS (from Escherichia coli, serotype 026:B6; Sigma-Aldrich,
St. Louis, MO, USA) or 0.1 μM STS (Sigma-Aldrich) for the indicated period of time.
BV6, pan-IAP antagonist bivalent compound (used at 1 μM), was generously
provided by Genentech, Inc. (South San Francisco, CA, USA).25
Protein extracts, immunoprecipitation and immunoblotting. Cyto-
plasmic and nuclear protein fractions were extracted in subcellular fractionation
buffer (150 mM NaCl, 50 mM HEPES pH 7.4, 0.5% NP40, 2 mM PMSF and
Protease Inhibitor Cockail) alternatively as reported by Joseph et al.32 Total protein
extracts were made directly in Laemmli buffer. For immunoprecipitation, cells were
lysed in an IP lysis buffer (20 mM Tris-HCl pH 7.5, 140 mM NaCl, 1% Triton-X100,
2 mM EDTA, 1 mM PMSF, 10% glycerol and Protease Inhibitor Cocktail) for 15 min
before sonication. Protein G Sepharose (GE Healthcare, Uppsala, Sweden)
precleared total protein extracts were incubated with the cleaved caspase-3
(Asp175) rabbit polyclonal antibody in IP lysis buffer overnight at 4 °C. Normal rabbit
IgG (# AB-105-C, R&D Systems, Minneapolis, MN, USA) was used as control.
Immunocomplexes bound to protein G Sepharose were collected by centrifugation
and washed in IP wash buffer (50 mM Tris-HCl, pH 7.5, 0.1% SDS, 1% NP40 and
62.5 mM NaCl). For immunoblot analysis, protein extracts were resolved on 12 or
15% SDS-polyacrylamide gel electrophoresis and then blotted onto nitrocellulose
membrane. Membranes were blocked in 5% milk and incubated with antibodies
raised against cIAP2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), cleaved
caspase-3 (Asp175) (Cell Signaling, Beverly, MA, USA), cleaved PARP (Cell
Signaling), G3PDH (Trevigen, Gaithersburg, MD, USA), iNOS (Santa Cruz
Biotechnology), Lamin B (Abcam, Cambridge, MA, USA) or H4 (Active Motif,
Carlsbad, CA, USA), overnight at 4 °C, followed by incubation with the appropriate
horseradish peroxidase secondary antibody (Pierce, Rockford, IL, USA, 1 : 10 000)
for 1 h at room temperature. Immunoblot with anti-β-actin antibody (Sigma) was
used for standardization of protein loading. Bands were visualized by enhanced
chemiluminescence (ECL-Plus, Pierce) following the manufacturer’s protocol.
Densitometry was done using ImageJ software (NIH, USA; http.//imagej.nih.gov/ij).
RNA isolation, cDNA synthesis and qPCR. RNA was isolated from
2 × 105 cells using the total RNA extraction kit (Qiagen, Courtaboeuf, France). cDNA
was synthesized from 1 μg RNA using Oligo dT, dNTPs and Superscript II
(Invitrogen). qPCR was performed using Sybr Green reagents (Applied Biosystems,
Waltham, MA, USA) and the following primers (forward; reverse): NOS2 (5ʹ-GTGGT
GACAAGCACATTTGG-3ʹ; 5ʹ-AAGGCCAAACACAGCATACC-3ʹ), IL-1β (5ʹ-GCTGCT
TCCAAACCTTTGAC-3ʹ; 5ʹ-TTCTCCACAGCCACAATGAG-3ʹ), cIAP1/BIRC2 (5ʹ-T
GATGGTGGCTTGAGATGTTGGGA-3ʹ; 5ʹ-TGAAT CTCATCAACAAACTCCTGACC
C-3ʹ), cIAP2/BIRC3 (5ʹ-TGTCAGCCAAGTTCAAGCTG-3ʹ; 5ʹ-ATCTTCCGAACTTT
CTCCAGGG-3ʹ), XIAP (5ʹ-CCATGTGTAGTGAAGAAGCCAGAT-3ʹ; 5ʹ-GATCATCA
GCCCCTGTGTAGTAG-3ʹ) and β-actin (5ʹ-TTGCTGACAGGATGCAGAAG-3ʹ;
5ʹ-TGATCCACATCTGCTGGAAG-3ʹ). Results were calculated using delta Ct
method.
Caspase activity assay. Changes in caspase activity in microglia were
measured using a luciferase-based assay from Promega (Stockholm, Sweden) known
as Caspase-Glo (G890 for caspase-3/7). Equal volumes of cells and kit component
were mixed onto a 96-well plate and incubated for 1 h at room temperature. The plate
was analyzed using a luminometer and the value obtained normalized with the number
of cells at harvest.
Cell death quantification. After treatment, cells were collected and
cytospins were prepared. Subsequently, DNA was stained with Hoechst 33342
(2 μg/ml; Molecular Probes/Invitrogen, Carlsbad, CA, USA). The number of dying
cells was measured quantitatively by assessing the percentage of cells with
fragmented, damaged or condensed nuclei.
FACS analysis. Appearance of subdiploid-fragmented nuclei derived from
apoptotic cells were analyzed after DNA staining with 0.5 μg/ml propidium iodide, in
the presence of 2.5 μg/ml RNase A in PBS, pH 7.4. Cleaved caspase-3 or cIAP2
expression was quantified in 0.25% paraformaldehyde-fixed cells following
described protocol.5 Alexa Fluor 488-conjugated secondary antibodies (Molecular
Probes/Invitrogen) were used for detection in the FL1 channel. For determination of
the external exposition of PS residues, staining with Annexin-V-FITC and propidium
iodide was used according to the manufacturer’s instructions (#V13242, FITC
Annexin V/Dead Cell Apoptosis kit, Invitrogen). Data are depicted in logarithmic
scales. Analyses were carried out on a FACScalibur flow cytometer equipped with
Cell Quest software (Becton Dickinson, Franklin Lakes, NJ, USA).
In situ PLA. Cells were seeded on coverslips and treated as indicated. After
treatment, cells were fixed with 4% paraformaldehyde in PBS. Protein–protein
interactions between cIAP2 and cleaved caspase-3 in fixed cells were detected
using the Duolink II in situ PLA from Olink Bioscience (Uppsala, Sweden). PLA was
performed in a humidity chamber. After incubation with the blocking buffer (3% BSA
and 0.3% Triton-X in PBS), cells were incubated with the primary antibodies mouse
anti-cIAP2 (1 : 5000, R&D Systems) and rabbit anti-cleaved caspase-3 (1 : 400, Cell
Signaling) antibodies, in the antibody diluent medium overnight at 4 °C. Cells were
washed with supplied buffer A and incubated for 1 h in a humidity chamber at 37 °C
with PLA probes detecting mouse or rabbit antibodies (Duolink II PLA probe anti-
rabbit plus and Duolink II PLA probe anti-mouse minus diluted in the antibody
diluent to a concentration of 1 : 5). After washing with buffer A, cells were incubated
for 30 min at 37 °C with the ligation solution (Duolink II Ligation stock 1 : 5 and
Duolink II Ligase 1 : 40). If the two protein targets are in close proximity, a template
is formed for amplification. Detection of the amplified probe was done with the
Duolink II Detection Reagents Red Kit. After repeated washing at room temperature
with wash buffer B, coverslips were mounted onto slides using mounting medium
containing DAPI and samples were observed using an epifluorescence microscope.
Protein–protein interaction was measured as the number of fluorescent dots/cell
analyzed with Duolink Image tool.
Statistical analysis. Statistical analysis was performed using Student's t-test.
Po0.05 was considered as statistically significant.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. We thank Drs S Ceccatelli (Karolinska Institutet) and
D Vucic (Genentech, Inc.) for providing us with the BV2 cell line and the BV6
compound, respectively. JR is supported by a fellowship from the Karolinska Institutet
Foundations and MAB is supported by a postdoctoral fellowship from the Swedish
Research Council. This work was supported by the Michael J Fox Foundation for
Parkinson’s Research, the Parkinson Foundation in Sweden, the Swedish Brain
Foundation, the Swedish Cancer Society, the Swedish Childhood Cancer Foundation
and the Swedish Research Council.
1. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev
Immunol 2011; 11: 775–787.
cIAP2 controls caspase-3 in activated microglia
E Kavanagh et al
8
Cell Death and Disease
2. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular
mechanisms. Nat Rev Neurosci 2007; 8: 57–69.
3. Venero JL, Burguillos MA, Brundin P, Joseph B. The executioners sing a new song: killer
caspases activate microglia. Cell Death Differ 2011; 18: 1679–1691.
4. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for
HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology
1988; 38: 1285–1291.
5. Burguillos MA, Deierborg T, Kavanagh E, Persson A, Hajji N, Garcia-Quintanilla A et al.
Caspase signalling controls microglia activation and neurotoxicity. Nature 2011; 472:
319–324.
6. Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P, Zhivotovsky B.
Defective caspase-3 relocalization in non-small cell lung carcinoma. Oncogene 2001; 20:
2877–2888.
7. Han Z, Hendrickson EA, Bremner TA, Wyche JH. A sequential two-step mechanism for the
production of the mature p17:p12 form of caspase-3 in vitro. J Biol Chem 1997; 272:
13432–13436.
8. Castano A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces
inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem
1998; 70: 1584–1592.
9. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG et al. A Nurr1/
CoREST pathway in microglia and astrocytes protects dopaminergic neurons from
inflammation-induced death. Cell 2009; 137: 47–59.
10. Kamada S, Kikkawa U, Tsujimoto Y, Hunter T. Nuclear translocation of caspase-3 is
dependent on its proteolytic activation and recognition of a substrate-like protein(s). J Biol
Chem 2005; 280: 857–860.
11. Luo M, Lu Z, Sun H, Yuan K, Zhang Q, Meng S et al. Nuclear entry of active
caspase-3 is facilitated by its p3-recognition-based specific cleavage activity. Cell Res 2010;
20: 211–222.
12. Voss OH, Batra S, Kolattukudy SJ, Gonzalez-Mejia ME, Smith JB, Doseff AI. Binding of
caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting
caspase-3 proteolytic activation. J Biol Chem 2007; 282: 25088–25099.
13. Silke J, Meier P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and
inflammation. Cold Spring Harb Perspect Biol 2013; 5.
14. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB,
inflammation and cancer. Nat Rev Cancer 2010; 10: 561–574.
15. Tenev T, Zachariou A, Wilson R, Ditzel M, Meier P. IAPs are functionally non-
equivalent and regulate effector caspases through distinct mechanisms. Nat Cell Biol
2005; 7: 70–77.
16. Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do
not inhibit caspases. J Biol Chem 2006; 281: 3254–3260.
17. Burke SP, Smith L, Smith JB. cIAP1 cooperatively inhibits procaspase-3 activation by the
caspase-9 apoptosome. J Biol Chem 2010; 285: 30061–30068.
18. Cui X, Imaizumi T, Yoshida H, Tanji K, Matsumiya T, Satoh K. Lipopolysaccharide induces
the expression of cellular inhibitor of apoptosis protein-2 in human macrophages. Biochim
Biophys Acta 2000; 1524: 178–182.
19. Conte D, Holcik M, Lefebvre CA, Lacasse E, Picketts DJ, Wright KE et al. Inhibitor
of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival.
Mol Cell Biol 2006; 26: 699–708.
20. Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T. The inhibitor
of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro
monoubiquitination of caspases 3 and 7. J Biol Chem 2000; 275: 26661–26664.
21. Durkop H, Hirsch B, Hahn C, Stein H. cIAP2 is highly expressed in Hodgkin-Reed-Sternberg
cells and inhibits apoptosis by interfering with constitutively active caspase-3. J Mol Med
(Berl) 2006; 84: 132–141.
22. Rajalingam K, Sharma M, Paland N, Hurwitz R, Thieck O, Oswald M et al. IAP-IAP
complexes required for apoptosis resistance of C. trachomatis-infected cells. PLoS Pathog
2006; 2: e114.
23. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome
c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33–42.
24. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE et al. Identification of
DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP
proteins. Cell 2000; 102: 43–53.
25. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al.
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and
TNFalpha-dependent apoptosis. Cell 2007; 131: 669–681.
26. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target
cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682–693.
27. Muller-Sienerth N, Dietz L, Holtz P, Kapp M, Grigoleit GU, Schmuck C et al. SMAC mimetic
BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells.
PloS One 2011; 6: e21556.
28. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M et al. Identification
and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;
376: 37–43.
29. D'Amelio M, Cavallucci V, Cecconi F. Neuronal caspase-3 signaling: not only cell death.
Cell Death Differ 2010; 17: 1104–1114.
30. Beug ST, Tang VA, Lacasse EC, Cheung HH, Beauregard CE, Brun J et al. Smac mimetics
and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 2014; 32:
182–190.
31. Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, Kettenmann H. An immortalized cell line
expresses properties of activated microglial cells. J Neurosci Res 1992; 31: 616–621.
32. Joseph B, Wallen-Mackenzie A, Benoit G, Murata T, Joodmardi E, Okret S et al. p57(Kip2)
cooperates with Nurr1 in developing dopamine cells. Proc Natl Acad Sci USA 2003; 100:
15619–15624.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
Licence. The images or other third party material in this article are
included in the article’s Creative Commons licence, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons licence, users will need to obtain permission from
the licence holder to reproduce the material. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
cIAP2 controls caspase-3 in activated microglia
E Kavanagh et al
9
Cell Death and Disease
